Satellos Bioscience Inc.
MSLEHealthcare|Biotechnology|CA
$7.19
+0.84 (+13.23%)
DCF Value
$4.97
Tangible Book / Share
$2.87
Cash / Share
$2.96
Financials
Financial Snapshot
Market Cap
$9.3M
Enterprise Value
$144.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$34.3M
Cash & Investments
$61.8M
Net Cash
$61.8M
Free Cash Flow (TTM)
-$28.7M
Operating CF (TTM)
-$28.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$61.8M
Quarterly Burn
$7.2M
Monthly Burn
$2.4M
Est. Runway
~8.6 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.4M | $1.1M | $10.1K | $1.0M | $719.2K | $3.8M | $1.9M | $39.6M | $48.7M | $27.7M | $61.8M | |
| Operating Cash Flow | -$1.3M | — | -$1.1M | -$2.3M | -$1.7M | -$3.9M | -$4.3M | -$14.4M | -$17.4M | -$23.6M | -$28.7M | |
| Free Cash Flow | -$1.3M | — | -$1.1M | -$2.3M | -$1.7M | -$4.0M | -$4.3M | -$14.4M | -$17.4M | -$23.6M | -$28.7M | |
| Capital Expenditure | -$4.1K | — | -$3.2K | -$6.2K | $0.00 | -$5.7K | -$2.2K | -$18.0K | -$4.2K | -$6.0K | -$7.0K | |
| Financing Cash Flow | $0.00 | — | $0.00 | $3.3M | $2.0M | $5.8M | $2.7M | $51.0M | $37.3M | $2.2M | $52.3M |
R&D Spending
R&D (TTM)
$26.1M
R&D Intensity
—
R&D Growth vs Prior
+41.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $568.8K | $798.5K | $1.4M | $942.5K | $892.8K | $2.0M | $3.7M | $6.6M | $13.7M | $18.4M | $26.1M | |
| SG&A | $643.8K | $672.5K | $777.3K | $1.3M | $987.5K | $2.6M | $4.7M | $4.6M | $5.2M | $7.4M | $8.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $27.6K | $23.8K | $1.5K | $3.1K | $892.8K | $166.9K | $3.7M | $5.3K | $20.0K | $5.1K | $4.0K | |
| Gross Profit | -$27.6K | -$23.8K | -$1.5K | -$3.1K | -$892.8K | -$166.9K | -$3.7M | -$5.3K | -$20.0K | -$5.1K | -$4.0K | |
| R&D | $568.8K | $798.5K | $1.4M | $942.5K | $892.8K | $2.0M | $3.7M | $6.6M | $13.7M | $18.4M | $26.1M | |
| SG&A | $643.8K | $672.5K | $777.3K | $1.3M | $987.5K | $2.6M | $4.7M | $4.6M | $5.2M | $7.4M | $8.8M | |
| Operating Income | -$1.2M | -$1.5M | -$2.2M | -$2.3M | -$2.8M | -$6.6M | -$8.4M | -$11.7M | -$19.4M | -$26.5M | -$35.5M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $499.00 | $772.8K | $0.00 | $133.4K | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$1.5M | -$1.3M | -$1.7M | -$2.3M | -$1.6M | -$15.5M | -$11.3M | -$12.0M | -$19.6M | -$24.7M | -$34.2M | |
| Net Income | -$1.5M | -$1.3M | -$1.7M | -$2.0M | -$1.6M | -$15.5M | -$11.3M | -$12.0M | -$19.6M | -$24.9M | -$34.3M | |
| EPS (Diluted) | -4.84 | -2.44 | -4.82 | -3.90 | -1.07 | -6.02 | -3.81 | -1.63 | -2.16 | -20.40 | -1.92 | |
| EBITDA | -$1.2M | -$1.5M | -$2.2M | -$2.3M | -$1.6M | -$4.7M | -$8.1M | -$11.8M | -$19.6M | -$26.5M | -$35.5M | |
| Shares Out. (M) | 0.35 | 0.35 | 0.35 | 0.51 | 1.48 | 2.01 | 2.97 | 7.20 | 9.56 | 1.22 | 20.83 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.4M | $1.1M | $10.1K | $1.0M | $709.1K | $3.8M | $1.9M | $22.1M | $40.2M | $9.8M | $7.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $10.1K | $0.00 | $0.00 | $17.5M | $8.5M | $17.9M | $54.4M | |
| Total Current Assets | $2.4M | $1.4M | $174.5K | $1.5M | $1.1M | $4.3M | $2.2M | $40.3M | $50.9M | $31.9M | $65.7M | |
| Total Assets | $2.5M | $1.4M | $177.6K | $1.5M | $1.1M | $9.9M | $6.1M | $44.3M | $50.9M | $31.9M | $65.7M | |
| Total Current Liabilities | $139.2K | $292.5K | $800.1K | $829.6K | $220.5K | $1.7M | $2.8M | $3.6M | $3.6M | $4.1M | $5.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $139.2K | $292.5K | $800.1K | $829.6K | $1.3M | $1.7M | $2.8M | $3.6M | $3.6M | $4.1M | $5.9M | |
| Stockholders' Equity | $2.3M | $1.1M | -$622.5K | $678.7K | -$184.3K | $8.2M | $3.3M | $40.7M | $47.3M | $27.8M | $59.8M | |
| Retained Earnings | -$32.3M | -$33.8M | -$34.9M | -$38.0M | -$4.8M | -$15.9M | -$31.3M | -$47.5M | -$52.7M | -$82.0M | -$103.3M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M | — | -$1.1M | -$2.3M | -$1.7M | -$3.9M | -$4.3M | -$14.4M | -$17.4M | -$23.6M | -$28.7M | |
| Capital Expenditure | -$4.1K | — | -$3.2K | -$6.2K | $0.00 | -$5.7K | -$2.2K | -$18.0K | -$4.2K | -$6.0K | -$7.0K | |
| Free Cash Flow | -$1.3M | — | -$1.1M | -$2.3M | -$1.7M | -$4.0M | -$4.3M | -$14.4M | -$17.4M | -$23.6M | -$28.7M | |
| Investing Cash Flow | -$4.1K | — | -$3.2K | -$6.2K | $0.00 | $1.4M | -$2.2K | -$17.5M | $4.4M | -$9.4M | -$54.2M | |
| Financing Cash Flow | $0.00 | — | $0.00 | $3.3M | $2.0M | $5.8M | $2.7M | $51.0M | $37.3M | $2.2M | $52.3M | |
| Issuance of Stock | $0.00 | — | $0.00 | $3.3M | $892.6K | $5.6M | $2.0M | $24.5M | $29.8M | $2.2M | $52.3M | |
| Repurchase of Stock | $0.00 | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | — | $0.00 | $0.00 | $1.1M | $146.3K | $0.00 | -$284.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | — | $0.00 | $0.00 | $0.00 | $762.0K | $1.1M | $1.6M | $1.5M | $3.2M | $1.8M | |
| Net Change in Cash | -$274.4K | — | -$1.2M | $1.0M | -$265.7K | $3.3M | -$1.2M | $21.3M | $24.8M | -$30.3M | -$30.8M |
Dilution Tracker
Shares Outstanding
1M
5-Year Share Growth
-17.8%
Stock Issuance (TTM)
$52.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.35 | 0.35 | 0.35 | 0.51 | 1.48 | 2.01 | 2.97 | 7.20 | 9.56 | 1.22 | 20.83 | |
| Change vs Prior % | — | 0.0% | 0.0% | 44.9% | 190.1% | 35.6% | 48.2% | 142.2% | 32.8% | -87.3% | 1612.7% | |
| Stock Issuance | $0.00 | — | $0.00 | $3.3M | $892.6K | $5.6M | $2.0M | $24.5M | $29.8M | $2.2M | $52.3M | |
| Stock Repurchase | $0.00 | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | — | $0.00 | $0.00 | $0.00 | $762.0K | $1.1M | $1.6M | $1.5M | $3.2M | $1.8M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -64.4% | -113.8% | 272.6% | -293.4% | 856.7% | -188.6% | -339.5% | -29.4% | -41.4% | -89.5% | -72.7% | |
| ROA % | -60.8% | -90.0% | -955.6% | -132.0% | -139.4% | -157.1% | -184.5% | -27.0% | -38.5% | -78.0% | -53.2% | |
| ROIC % | -53.2% | -135.5% | 352.6% | -293.7% | -304.2% | -80.9% | -252.6% | -28.7% | -41.0% | -95.2% | -60.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -25.8% | 13.7% | 93.6% | -105.2% | -28278.3% | 81.3% | -2136.7% | 99.9% | -278.4% | 74.5% | |
| Operating Income | 43.8% | -20.5% | -46.8% | -3.2% | -22.4% | -139.7% | -26.8% | -38.3% | -66.2% | -36.6% | |
| Net Income | 16.2% | 16.4% | -35.2% | -17.3% | 20.7% | -882.3% | 27.0% | -5.8% | -63.5% | -27.0% | |
| EPS (Diluted) | -1.0% | 49.6% | -97.5% | 19.1% | 72.6% | -462.6% | 36.7% | 57.2% | -32.5% | -844.4% | |
| Operating Cash Flow | 56.5% | 0.0% | 0.0% | -108.8% | 27.6% | -137.3% | -7.9% | -238.4% | -20.7% | -35.6% | |
| Free Cash Flow | 56.4% | 0.0% | 0.0% | -108.7% | 27.8% | -137.6% | -7.8% | -238.6% | -20.6% | -35.6% | |
| R&D Expense | -9.1% | 40.4% | 77.3% | -33.4% | -5.3% | 124.4% | 86.4% | 78.0% | 105.5% | 34.9% | |
| SG&A Expense | -58.7% | 4.5% | 15.6% | 69.8% | -25.2% | 165.7% | 78.9% | -2.7% | 13.0% | 44.1% | |
| Total Assets | -36.4% | -43.5% | -87.3% | 749.2% | -24.9% | 772.0% | -37.8% | 621.8% | 14.8% | -37.3% | |
| Book Value / Share | -38.2% | -52.7% | -156.4% | 175.2% | -109.4% | 3389.1% | -72.6% | 403.5% | -12.5% | 362.1% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 44.9% | 190.1% | 35.6% | 48.2% | 142.2% | 32.8% | -87.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.50
10Y Low / Med / High0.31 / 2.18 / 8.55
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$4.97
Tangible Book / Share
$2.87
Net Current Assets / Share
$46.42
Graham Net-Net
$2.71
Cash / Share
$2.96
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1.97 | -3.65 | -2.00 | -2.36 | -8.44 | -1.49 | -2.52 | -5.75 | -4.71 | -0.35 | -3.62 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1.44 | 2.84 | -5.46 | 6.90 | -72.49 | 2.18 | 8.55 | 1.66 | 2.06 | 0.31 | 2.50 | |
| EV/EBITDA | -0.80 | -1.35 | -1.55 | -1.62 | -8.54 | -2.99 | -3.28 | -3.84 | -2.92 | 0.05 | -4.03 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-1.55
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $20.4M |
| Net Income | -$2.9M | -$2.9M | -$2.9M |
| EPS | $-2.37 | $-2.42 | $-2.40 |
| # Analysts (EPS) | 4 | 5 | 2 |